Dolastatin 15
Dolastatin 15 (DLS 15), a depsipeptide derived from Dolabella auricularia, is a potent antimitotic agent structurally related to the antitubulin agent Dolastatin 10. Dolastatin 15 induces cell cycle arrest and apoptosis in multiple myeloma cells. Dolastatin 15 can be used as an ADC cytotoxin.
For research use only. We do not sell to patients.
- CAS No.: 123884-00-4
- Formula: C45H68N6O9
- Molecular Weight:837.06
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
Auristatin |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CTLL | IC50 |
3 nM
Compound: 1 (4S,7S)(Dolastatin 15)
|
In vitro interleukin-2-dependent proliferation of the murine cytotoxlc T cell line (CTLL) was determined
In vitro interleukin-2-dependent proliferation of the murine cytotoxlc T cell line (CTLL) was determined
|
10.1016/S0960-894X(01)80540-0 |
| HT-29 | IC50 |
0.29 nM
Compound: dolastatin 15
|
Inhibitory activity against growth of HT-29 cell line
Inhibitory activity against growth of HT-29 cell line
|
[PMID: 9554885] |
| Jurkat | IC50 |
5 nM
Compound: 1 (4S,7S)(Dolastatin 15)
|
In vitro growth factor-independent proliferation against human leukemia T cell line jurkat was determined
In vitro growth factor-independent proliferation against human leukemia T cell line jurkat was determined
|
10.1016/S0960-894X(01)80540-0 |
| L1210 | IC50 |
0.13 nM
Compound: dolastatin 15
|
Inhibitory activity against growth of L1210 cell line
Inhibitory activity against growth of L1210 cell line
|
[PMID: 9554885] |
| L1210 | IC50 |
0.15 nM
Compound: 1 (4S,7S)(Dolastatin 15)
|
In vitro growth factor-independent proliferation against murine leukemia L1210 was determined
In vitro growth factor-independent proliferation against murine leukemia L1210 was determined
|
10.1016/S0960-894X(01)80540-0 |
| Lymphoma cell line | IC50 |
0.012 nM
Compound: 1 (4S,7S)(Dolastatin 15)
|
Antiproliferative effect against human lymphoma cells was determined; (0.012 to 0.12 nM)
Antiproliferative effect against human lymphoma cells was determined; (0.012 to 0.12 nM)
|
10.1016/S0960-894X(01)80540-0 |
| MCF7 | IC50 |
0.04 nM
Compound: dolastatin 15
|
Inhibitory activity against growth of MCF-7 cell line
Inhibitory activity against growth of MCF-7 cell line
|
[PMID: 9554885] |
| Osteoclast-like | IC50 |
17 nM
Compound: 1 (4S,7S)(Dolastatin 15)
|
In vitro growth factor-dependent proliferation against murine bone marrow cell was determined
In vitro growth factor-dependent proliferation against murine bone marrow cell was determined
|
10.1016/S0960-894X(01)80540-0 |
| P388 | ED50 |
2.4 ng/mL
Compound: Dolastatin15
|
Anticancer activity against lymphocytic leukemia P388 cells was determined
Anticancer activity against lymphocytic leukemia P388 cells was determined
|
[PMID: 9871690] |
| Panel leukemia (Carcinoma cell lines) | IC50 |
0.1 nM
Compound: 1 (4S,7S)(Dolastatin 15)
|
Antiproliferative effect against continuous human leukemia cell lines and peripheral blood cells from patients with acute myeloid leukemia was determined; (0.1 to 1 nM)
Antiproliferative effect against continuous human leukemia cell lines and peripheral blood cells from patients with acute myeloid leukemia was determined; (0.1 to 1 nM)
|
10.1016/S0960-894X(01)80540-0 |
In Vitro
Dolastatin 15 (DLS 15) induces cell cycle arrest at the G2/M phase followed by apoptosis in various human myeloma cell lines (RPMI8226, U266, and IM9). Dolastatin 15 induces apoptosis of myeloma cells via activation of both mitochondrial- and Fas (CD95)/Fas-L (CD95-L)-mediated pathways[2].
Dolastatin 15 (DLS 15) displays growth inhibitory activity against all four SCLC cell lines (NCI-H69, NCI-H82, NCI-H345, NCI-H446) with IC50 values ranging from 0.039-28.8 nM, which were 2.7-9.2-fold higher than the values for dolastatin 10. All four SCLC cell lines underwent G2/M arrest within 24 hours of exposure to dolastatin 15[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 123884-00-4
-
Molecular Weight 837.06
-
Formula C45H68N6O9
-
Synonyms
DLS 15
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
References
[1]. Bai R, et al. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol. 1992 Jun 23;43(12):2637-45. [Content Brief]
[2]. Sato M, et al. A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells. Int J Oncol. 2007 Jun;30(6):1453-9. [Content Brief]
[3]. Gianolio DA, et al. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Cancer Chemother Pharmacol. 2012 Sep;70(3):439-49. [Content Brief]
[4]. Ali MA, et al. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines. Anticancer Res. 1998 Mar-Apr;18(2A):1021-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)